Vestal Point Capital »

Enliven Therapeutics shares owned by Vestal Point Capital

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Vestal Point Capital from 13F filings

Historical chart of Vestal Point Capital investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Vestal Point Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $24M 1.2M 20.47
2025-06-30 $5.0M 250k 20.06

More positions owned by Vestal Point Capital

Ascendis Pharma A/S Sponsored Adr (ASND)
Arcellx Common Stock (ACLX)
Nuvalent Inc-a (NUVL)
Abivax SA Sponsored Ads (ABVX)
Alcon Ord Shs (ALC)
Bicara Therapeutics (BCAX)
Amicus Therapeutics (FOLD)
Globus Medical Cl A (GMED)
Ionis Pharmaceuticals (IONS)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Becton, Dickinson and (BDX)
Scholar Rock Hldg Corp (SRRK)
Immatics NV SHS (IMTX)
Repligen Corporation (RGEN)
Dianthus Therapeutics (DNTH)

View all positions for Vestal Point Capital

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Fairmount Funds Management
BlackRock
VR Adviser
Polar Capital Holdings
Vanguard Group
Henderson Group
Novo A/S
Pictet Asset Management Holding SA
Blackstone Group
Capital Research Global Investors
Citadel Advisors
Vestal Point Capital

View all funds holding Enliven Therapeutics